{"product_id":"triumeq-abacavir-dolutegravir-lamivudine","title":"TRIUMEQ (Abacavir\/Dolutegravir\/ Lamivudine)","description":"\u003ch5 data-mce-fragment=\"1\"\u003eWhat is this medication?\u003c\/h5\u003e\n\u003cp data-mce-fragment=\"1\"\u003e\u003cspan data-mce-fragment=\"1\"\u003e\u003cstrong\u003eTRIUMEQ (Abacavir\/Dolutegravir\/Lamivudine)\u003c\/strong\u003e\u003cbr data-mce-fragment=\"1\"\u003eAntiretroviral, Integrase Inhibitor (Anti-HIV); Antiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV)\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eALERT: WARNING\u003cbr\u003e\u003c\/b\u003e\u003cspan style=\"font-weight: 400;\"\u003eSerious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir. Patients who carry the HLA-B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele. TRIUMEQ (Abacavir\/Dolutegravir\/Lamivudine) is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients. All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with abacavir\/dolutegravir\/lamivudine or reinitiation of therapy with abacavir\/dolutegravir\/lamivudine unless patients have a previously documented HLA-B*5701 allele assessment. Discontinue abacavir\/dolutegravir\/lamivudine immediately if a hypersensitivity reaction is suspected, regardless of status and even when other diagnoses are possible.  Following a hypersensitivity reaction to abacavir\/dolutegravir\/lamivudine, never restart abacavir\/dolutegravir\/lamivudine or any other abacavir-containing product because more severe symptoms, including death, can occur within hours. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eSevere acute exacerbations of hepatitis B have been reported in patients who are coinfected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1) and have discontinued lamivudine. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue abacavir\/dolutegravir\/lamivudine and are coinfected with HIV-1 and HBV.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch5 data-mce-fragment=\"1\"\u003eHow does this medication work?\u003c\/h5\u003e\n\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eTRIUMEQ, contains a combination of dolutegravir (integrase strand transfer inhibitor), abacavir, and lamivudine (both nucleoside analogue reverse transcriptase inhibitors). \u003c\/span\u003e\u003cspan style=\"font-weight: 400;\"\u003eDolutegravir blocks the integrase active site and prevents the step of retroviral integration resulting in inhibition of HIV integrase.  Abacavir is converted to the active metabolite, carbovir triphosphate which inhibits the activity of HIV-1 reverse transcriptase both by competing with dGTP and by its incorporation into viral DNA. Lamivudine is phosphorylated within the cell to its active 5′-triphosphate metabolite, lamivudine triphosphate. This active metabolite inhibits reverse transcriptase via DNA chain termination after incorporation of the nucleotide analogue.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch5 data-mce-fragment=\"1\"\u003e\u003cspan data-mce-fragment=\"1\"\u003eHow should I take this medication?\u003c\/span\u003e\u003c\/h5\u003e\n\u003cp data-mce-fragment=\"1\"\u003e\u003cem\u003eOral:\u003c\/em\u003e\u003cspan\u003e Take o\u003c\/span\u003e\u003cspan\u003ene tablet (abacavir 600 mg\/dolutegravir 50 mg\/lamivudine 300 mg) once daily.\u003c\/span\u003e\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e\u003cb\u003eHow to Take: \u003c\/b\u003e\u003cspan\u003eAdminister with or without food. If patient is also taking certain medications, an additional daily single-component dolutegravir tablet should be administered 12 hours after TRUIMEQ. Administer 2 hours before or 6 hours after cation-containing antacids or laxatives, sucralfate, oral supplements containing iron or calcium, or buffered medications. It may be administered with supplements containing calcium or iron at the same time if administered together with food.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch5 data-mce-fragment=\"1\"\u003e\u003cspan data-mce-fragment=\"1\"\u003eWhat should I watch for while using this medication?\u003c\/span\u003e\u003c\/h5\u003e\n\u003cp data-mce-fragment=\"1\"\u003e\u003cspan\u003eBefore starting TRIUMEQ (Abacavir\/Dolutegravir\/ Lamivudine)\u003c\/span\u003e\u003cspan\u003e \u003c\/span\u003e\u003cspan\u003emake sure your physician is aware of any allergies or medications you currently take, if you have the \u003c\/span\u003e\u003ci\u003e\u003cspan\u003eHLA-B*5701\u003c\/span\u003e\u003c\/i\u003e\u003cspan\u003e allele,\u003c\/span\u003e\u003cspan\u003e if you have \u003c\/span\u003e\u003cspan\u003echronic hepatitis B, coronary heart disease, lamivudine resistant hepatitis B, liver disease, or kidney disease\u003c\/span\u003e\u003cspan\u003e. TRIUMEQ (Abacavir\/Dolutegravir\/ Lamivudine)\u003c\/span\u003e\u003cspan\u003e \u003c\/span\u003e\u003cspan\u003euse has been associated with rare but serious adverse events such as \u003c\/span\u003e\u003cspan\u003ehepatotoxicity, hypersensitivity reactions, immune reconstitution syndrome, lactic acidosis, hepatomegaly, pancreatitis.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch5 data-mce-fragment=\"1\"\u003e\u003cspan data-mce-fragment=\"1\"\u003eWhat if I miss a dose?\u003c\/span\u003e\u003c\/h5\u003e\n\u003cp data-mce-fragment=\"1\"\u003e\u003cspan data-mce-fragment=\"1\"\u003eIf you miss a dose of medication, try to take it as soon as possible. However, if it is almost time for your next dose, take only that scheduled dose. Do not take double or extra doses.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch5 data-mce-fragment=\"1\"\u003e\u003cspan data-mce-fragment=\"1\"\u003eHow should I store this medication?\u003c\/span\u003e\u003c\/h5\u003e\n\u003cp data-mce-fragment=\"1\"\u003e\u003cspan data-mce-fragment=\"1\"\u003eKeep out of the reach of children at all times. Store at room temperature, 59 to 86° F (15 to 30° C). Protect from light. Keep the container tightly closed. Properly dispose of any unused medication after the expiration date.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch5 data-mce-fragment=\"1\"\u003e\u003cspan data-mce-fragment=\"1\"\u003eWhat are the possible side effects of using this medication?\u003c\/span\u003e\u003c\/h5\u003e\n\u003cp\u003e\u003cspan\u003eHyperglycemia, increased serum lipase, increased creatine phosphokinase, headache, fatigue, malaise, parethsia, peripheral neuropathy, neuropathy, sleep disorders, rash, nausea, diarrhea, pancreatitis, sore throat, vomiting, neutropenia, increased liver enzymes, increased rate of infection, myalgia, cough, nasal congestion, fever.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eNote this is not a complete list of side effects for TRIUMEQ (Abacavir\/Dolutegravir\/Lamivudine), \u003c\/span\u003e\u003cspan\u003eonly common ones.\u003c\/span\u003e\u003c\/p\u003e","brand":"VIIV HEALTHCARE","offers":[{"title":"50\/600\/300mg - 30 Tab - Canada","offer_id":47149608632638,"sku":null,"price":2440.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0711\/0321\/7982\/products\/Triumeq.jpg?v=1695212650","url":"https:\/\/www.advochealth.com\/products\/triumeq-abacavir-dolutegravir-lamivudine","provider":"AdvocHealth","version":"1.0","type":"link"}